Your browser doesn't support javascript.
loading
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.
Budhu, Anuradha; Pehrsson, Erica C; He, Aiwu; Goyal, Lipika; Kelley, Robin Kate; Dang, Hien; Xie, Changqing; Monge, Cecilia; Tandon, Mayank; Ma, Lichun; Revsine, Mahler; Kuhlman, Laura; Zhang, Karen; Baiev, Islam; Lamm, Ryan; Patel, Keyur; Kleiner, David E; Hewitt, Stephen M; Tran, Bao; Shetty, Jyoti; Wu, Xiaolin; Zhao, Yongmei; Shen, Tsai-Wei; Choudhari, Sulbha; Kriga, Yuliya; Ylaya, Kris; Warner, Andrew C; Edmondson, Elijah F; Forgues, Marshonna; Greten, Tim F; Wang, Xin Wei.
Afiliación
  • Budhu A; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pehrsson EC; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Advanced Biom
  • He A; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
  • Goyal L; Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Kelley RK; Department of Medicine (Hematology/Oncology), UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA.
  • Dang H; Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center, Philadelphia, PA 19107, USA.
  • Xie C; Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Monge C; Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Tandon M; CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Ma L; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Revsine M; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Kuhlman L; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
  • Zhang K; Department of Medicine (Hematology/Oncology), UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA.
  • Baiev I; Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Lamm R; Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center, Philadelphia, PA 19107, USA.
  • Patel K; Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center, Philadelphia, PA 19107, USA.
  • Kleiner DE; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 21701, USA.
  • Hewitt SM; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 21701, USA.
  • Tran B; Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Shetty J; Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Wu X; Genomics Technology Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Zhao Y; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Shen TW; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Choudhari S; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Kriga Y; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Ylaya K; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 21701, USA.
  • Warner AC; Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Edmondson EF; Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Forgues M; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Greten TF; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethe
  • Wang XW; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address:
Cell Rep Med ; 4(6): 101052, 2023 06 20.
Article en En | MEDLINE | ID: mdl-37224815
Primary liver cancer is a rising cause of cancer deaths in the US. Although immunotherapy with immune checkpoint inhibitors induces a potent response in a subset of patients, response rates vary among individuals. Predicting which patients will respond to immune checkpoint inhibitors is of great interest in the field. In a retrospective arm of the National Cancer Institute Cancers of the Liver: Accelerating Research of Immunotherapy by a Transdisciplinary Network (NCI-CLARITY) study, we use archived formalin-fixed, paraffin-embedded samples to profile the transcriptome and genomic alterations among 86 hepatocellular carcinoma and cholangiocarcinoma patients prior to and following immune checkpoint inhibitor treatment. Using supervised and unsupervised approaches, we identify stable molecular subtypes linked to overall survival and distinguished by two axes of aggressive tumor biology and microenvironmental features. Moreover, molecular responses to immune checkpoint inhibitor treatment differ between subtypes. Thus, patients with heterogeneous liver cancer may be stratified by molecular status indicative of treatment response to immune checkpoint inhibitors.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_digestive_diseases / 6_liver_cancer Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_digestive_diseases / 6_liver_cancer Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
...